Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | VDR | P11473 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | BRS3 | P32247 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PRKCG | P05129 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041630 | 0.87 | ALDH1A1 (0.43) | ALDH1A1BRS3SMN1; SMN2PRKCGPRKCA | |
| SCHEMBL13041639 | 0.85 | PARP1 (0.43) | ALDH1A1BRS3SMN1; SMN2PRKCGPRKCA | |
| SCHEMBL13041643 | 0.83 | ALOX15 (0.36) | ALDH1A1BRS3SMN1; SMN2PRKCGPRKCA | |
| SCHEMBL13041634 | 0.83 | PARP1 (0.43) | ALDH1A1BRS3PARP1 | |
| SCHEMBL13041635 | 0.83 | PARP1 (0.43) | ALDH1A1SMN1; SMN2PARP1 | |
| SCHEMBL13041640 | 0.80 | PARP1 (0.44) | PARP1 | |
| SCHEMBL13041631 | 0.80 | ENPP2 (0.51) | BRS3SMN1; SMN2OPRM1OPRL1PARP1 | |
| SCHEMBL13041641 | 0.79 | BRD4 (0.41) | ALDH1A1BRS3SMN1; SMN2OPRM1OPRL1 | |
| SCHEMBL13015326 | 0.79 | BRD4 (0.42) | ALDH1A1SMN1; SMN2OPRM1OPRL1DPP4 | |
| SCHEMBL13041644 | 0.76 | OPRL1 (0.42) | OPRM1OPRL1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | ALDH1A1 2596/4885VDR 976/4885GRM2 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.